Comparison of 10 and 12-Core Prostate Biopsy Efficiencies in Patients with PSA<20 ng/ml

INTRODUCTION: Transrectal ultrasound-guided prostate biopsy (TRUS-B) is the gold standard method used to diagnose prostate cancer. However, how many samples should be taken in TRUS-B procedure is still controversial. The aim of this study is to compare the cancer detection rates of standard 10-core and 12-core TRUS-B procedures.
METHODS: Patients who underwent 10-core (Group-1) or 12-core (Group-2) TRUS-B operations were included in this retrospective study for prostate specific antigen (PSA) elevation or suspicious digital examination findings. Patients with PSA>20 ng/ml and a history of negative biopsy were excluded from the study. In addition to cancer detection rates of groups, demographic and clinical data such as age, body mass index (BMI), serum PSA ratios and prostate volume were compared.
RESULTS: A total of 208 patients were included in the study (Group-1: 98, Group-2: 110). The rate of cancer detection was 43.2% in all patients included in the study. The rates of cancer detection for 10-core and 12-core TRUS-B groups were similar (41.8%, 44.5%, p=0.694, respectively). Besides, there was no significant difference between the mean BMI, median age, prostate volume and PSA values of the groups. Urinary tract infection with fever was found to be higher in 12 patients with TRUS-B but the difference was not statistically significant (3.06% and 4.54%, p=0.578).
DISCUSSION AND CONCLUSION: The 10-core prostate biopsy appears to be a more applicable biopsy method than the 12-core TRUS-B procedure because of requires less sampling, similar cancer detection and complication rates.

PSA<20 Ng/Ml Hastalarda 10 ve 12 Kor Prostat Biyopsisi Etkinliklerinin Karþýlaþtýrýlmasý

GÝRÝÞ ve AMAÇ: Transrektal ultrasonografi kýlavuzluðunda yapýlan prostat biyopsisi (TRUS-B) prostat kanseri tanýsýný koymada kullanýlan altýn standart metottur. Ancak TRUS-B iþleminde kaç kor örnek alýnmasý gerektiði konusu hala tartýþmalýdýr. Bu çalýþmada standart 10 kor ve 12 kor TRUS-B iþlemlerinin kanser saptama oranlarýnýn karþýlaþtýrýlmasý amaçlanmýþtýr.
YÖNTEM ve GEREÇLER: Retrospektif özellikteki bu çalýþmaya prostat spesifik antijen (PSA) yüksekliði veya þüpheli dijital muayene bulgusu nedeniyle 10 kor (Grup-1) veya 12 kor (Grup-2) TRUS-B iþlemi uygulanmýþ hastalar dahil edilmiþtir. PSA>20 ng/ml olan ve daha önce negatif biyopsi öyküsü olan hastalar çalýþma dýþý býrakýlmýþtýr. Gruplarýn kanser tespit edilme oranlarýnýn yaný sýra yaþ, vücut kitle indeksi (VKÝ), serum PSA oranlarý ve prostat hacmi gibi demografik ve klinik verileri karþýlaþtýrýlmýþtýr.
BULGULAR: Çalýþmaya toplam 208 hasta dahil edildi (Grup-1: 98, Grup-2: 110). Çalýþmaya dahil edilen tüm hastalarda kanser tespit edilme oraný %43.2 idi. 10 kor ve 12 kor TRUS-B gruplarý için kanser tespit edilme oranlarý ise benzerdi (sýrasýyla %41.8, %44.5, p=0.694). Bunun yanýnda gruplarýn ortalama VKÝ, ortanca yaþ, prostat hacmi ve PSA deðerleri arasýnda anlamlý fark yoktu. Ateþli üriner sistem enfeksiyonu 12 kor TRUS-B uygulanan hastalarda daha yüksek oranda görülse de aradaki fark istatistiksel olarak anlamlý deðildi (%3.06 ve %4.54, p=0.578).
TARTIÞMA ve SONUÇ: 10 kor prostat biyopsisi, hastadan daha az örnek alýnmasý, benzer kanser tespit etme ve komplikasyon oranlarý nedeniyle 12 kor TRUS-B iþlemine göre daha uygulanabilir bir biyopsi yöntemi gibi görünmektedir.